N. Zhang, Xiao-Feng Li, Yongqiang Deng, H. Zhao, Yi-Jiao Huang, G. Yang, Wei-jin Huang, Peng Gao, Chao Zhou, Rong-Rong Zhang, Y. Guo, Shihui Sun, H. Fan, Shulong Zu, Qi Chen, Qi He, Tian-Shu Cao, Xing-Yao Huang, H. Qiu, J. Nie, Yuhang Jiang, Huaxiao Yan, Q. Ye, Xia Zhong, Xia Xue, Z. Zha, Dongsheng Zhou, Xiao Yang, You-Chun Wang, B. Ying, C. Qin
Cell, 2020
Summary There has been an urgent need of vaccines against coronavirus disease 2019 (COVID-19) due to the ongoing SARS-CoV-2 pandemic. Among all approaches, messenger RNA (mRNA) -based vaccine has emerged as a rapid and versatile platform to quickly respond to such a challenge. Here, we developed a lipid-nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (termed ARCoV). Intramuscular immunization of ARCoV mRNA-LNPs elicited robust neutralizing antibodies against SARS-CoV-2 as well as Th1-biased cellular response in mice and non-human primates. Two doses of ARCoV immunization in mice conferred complete protection against the challenge of a SARS-CoV-2 mouse adapted strain. Additionally, ARCoV was manufactured in liquid formulation and can be stored at room temperature for at least one week. This novel COVID-19 mRNA vaccine, ARCoV, is currently being evaluated in phase 1 clinical trials.
Cited by 124 publications.
Field of study: Medicine